C4 Therapeutics (CCCC) Income towards Parent Company: 2019-2025
Historic Income towards Parent Company for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to -$32.2 million.
- C4 Therapeutics' Income towards Parent Company fell 30.41% to -$32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$119.1 million, marking a year-over-year decrease of 12.88%. This contributed to the annual value of -$105.3 million for FY2024, which is 20.51% up from last year.
- According to the latest figures from Q3 2025, C4 Therapeutics' Income towards Parent Company is -$32.2 million, which was down 23.62% from -$26.0 million recorded in Q2 2025.
- In the past 5 years, C4 Therapeutics' Income towards Parent Company registered a high of -$15.7 million during Q4 2021, and its lowest value of -$35.9 million during Q2 2023.
- Its 3-year average for Income towards Parent Company is -$29.3 million, with a median of -$28.4 million in 2024.
- Its Income towards Parent Company has fluctuated over the past 5 years, first tumbled by 109.21% in 2021, then surged by 50.68% in 2024.
- C4 Therapeutics' Income towards Parent Company (Quarterly) stood at -$15.7 million in 2021, then plummeted by 75.07% to -$27.4 million in 2022, then dropped by 26.78% to -$34.8 million in 2023, then climbed by 0.52% to -$34.6 million in 2024, then slumped by 30.41% to -$32.2 million in 2025.
- Its Income towards Parent Company was -$32.2 million in Q3 2025, compared to -$26.0 million in Q2 2025 and -$26.3 million in Q1 2025.